Holen Sie sich die Stockscreener-App
6.12
1.83%
0.11
Handel nachbörslich:
5.90
-0.22
-3.59%
Schlusskurs vom Vortag:
$6.01
Offen:
$5.82
24-Stunden-Volumen:
51,555
Relative Volume:
1.08
Marktkapitalisierung:
$175.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.85%
1M Leistung:
+82.69%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.80
$6.20
1-Wochen-Bereich:
$5.50
$6.55
52-Wochen-Spanne:
$2.33
$6.76
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Firmenname
Insight Molecular Diagnostics Inc
Sektor
Branche
Telefon
949-409-7600
Adresse
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Vergleichen Sie IMDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
6.12 | 172.00M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
564.88 | 213.17B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
214.06 | 152.13B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
722.94 | 50.36B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
144.69 | 41.49B | 6.79B | 1.22B | 1.09B | 4.2644 |
|
IQV
Iqvia Holdings Inc
|
213.88 | 36.86B | 15.90B | 1.28B | 2.21B | 7.2842 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-28 | Eingeleitet | Lake Street | Buy |
| 2022-05-24 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Eingeleitet | Stephens | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-03-17 | Fortgesetzt | Needham | Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Eingeleitet | BTIG Research | Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Bestätigt | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Eingeleitet | Needham | Buy |
| 2019-02-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-01-29 | Hochstufung | Janney | Neutral → Buy |
| 2018-12-19 | Fortgesetzt | Lake Street | Buy |
Alle ansehen
Insight Molecular Diagnostics Inc Aktie (IMDX) Neueste Nachrichten
iMDx (NASDAQ: IMDX) schedules Q3 results for Nov 10, to attend Stephens conference - Stock Titan
What MACD trends signal for Insight Molecular Diagnostics Inc. (7OC0) stockEarnings Growth Report & Stepwise Entry/Exit Trade Alerts - newser.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock a buy for dividend portfoliosWeekly Loss Report & Safe Capital Growth Tips - newser.com
Will Insight Molecular Diagnostics Inc. (7OC0) stock boost dividends furtherPortfolio Risk Report & Weekly High Potential Stock Alerts - newser.com
U.S., Europe, and Asia Pacific Molecular Diagnostics Market - openPR.com
Is Insight Molecular Diagnostics Inc. (7OC0) stock included in top ETFs2025 EndofYear Setup & Daily Growth Stock Investment Tips - newser.com
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), TransMedics Group (TMDX) and Opko Health (OPK) - The Globe and Mail
Insight Molecular Diagnostics Advances Kidney Transplant Monitoring with New Study - TipRanks
Is Insight Molecular Diagnostics Inc. (7OC0) stock dividend growth reliablePortfolio Update Report & Weekly Setup with High ROI Potential - newser.com
On the Move: Oct. 21, 2025 - Nashville Post
BillionToOne IPO (BLLN.US): Unique Financial Profile For Molecular Diagnostics Company, Strong Buy - Smartkarma
US Market Wrap: What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stockWeekly Investment Summary & Technical Buy Zone Confirmation - Trung tâm Dự báo KTTV quốc gia
What earnings margins imply for Insight Molecular Diagnostics Inc. (7OC0) stock2025 Bull vs Bear & Comprehensive Market Scan Insights - Trung tâm Dự báo KTTV quốc gia
Returns Recap: Will Insight Molecular Diagnostics Inc. (7OC0) stock maintain strong growthWeekly Risk Report & Consistent Profit Trade Alerts - Trung tâm Dự báo KTTV quốc gia
Insight Molecular Diagnostics names Steven Tahmooressi as VP, marketing - Medical Buyer
Insight Molecular Diagnostics appoints Steven Tahmooressi as VP of Marketing - Investing.com Nigeria
Imdx welcomes new VP Marketing to prepare for commercial transplant assay launch - MarketScreener
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch - GlobeNewswire
GraftAssureDx kit launching 2026: iMDx hires Steven Tahmooressi as VP Marketing to lead global rollout - Stock Titan
Will Insight Molecular Diagnostics Inc. (7OC0) stock attract long term capital inflowsQuarterly Profit Report & Accurate Technical Buy Alerts - newser.com
Bullish Insight Molecular Diagnostics Insiders Rewarded As Their Investment Rises To US$4.85m - simplywall.st
Insight Molecular Diagnostics Inc.'s (NASDAQ:IMDX) large hedge funds owners must be happy as stock continues to impress, up 12% over the past week - Yahoo Finance
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring - Sahm
Insight Molecular Diagnostics stock rises after transplant study publication - Investing.com
Insight Molecular Says GraftAssure Assay Helped Avoid Overtreatment in Kidney Transplant Patient - MarketScreener
IMDX's GraftAssure Assay Shows Promise in Kidney Transplant Moni - GuruFocus
GraftAssure test helps monitor kidney transplant patient during cancer therapy - Investing.com
Finanzdaten der Insight Molecular Diagnostics Inc-Aktie (IMDX)
Es liegen keine Finanzdaten für Insight Molecular Diagnostics Inc (IMDX) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.64%
1.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):